Search Results for "CT P6 Celltrion"

12:00 EST 22nd December 2014 | BioPortfolio

Matching Channels


Matching News

Celltrion, Hospira to co-market biogenerics

Celltrion Inc. (biosimilars of blockbuster biologics), its Celltrion Healthcare division, and Hospira Inc. (specialty generic injectables) will collaborate on the manufacturing and supply of eight bio...

Celltrion files for Approval of Remicade Biosimilar in US

Celltrion, a Korean biotech, filed with the FDA for approval of Remsima®, a biosimilar to Janssen’s Remicade, which is indicated for autoimmune diseases. Remsima is the first monoclonal anti...

S. Korea's Celltrion says top shareholder drops plan to sell stake

SEOUL, July 2 (Reuters) - Celltrion Inc said on Wednesday its top shareholder is no longer considering a sale of a stake in the biotechnology company.

Celltrion to target US next for Remicade biosim approval

Following a Japanese approval last week Celltrion and partner Nippon Kayaku have claimed the US as the next target market for their Remicade (infliximab) biosimilar.

Celltrion submits first biosimilar mAb application to FDA

Celltrion Inc. (KOSDAQ:068270) submitted an application to FDA for Remsima infliximab, a biosimilar of Remicade from Johnson & Johnson (NYSE:JNJ) and

Celltrion Eyes U.S. As Next Target For Remicade Biosimilar Approval

South Korea’s Celltrion and Japanese partner Nippon Kayaku eye the U.S. for the next approval of their biosimilar of Johnson & Johnson’s Remicade.

Celltrion grants Remsima marketing rights to Mundipharma

Celltrion Inc. (KOSDAQ:068270) subsidiary Celltrion Healthcare Hungary Kft granted Mundipharma International Ltd. (Cambridge, U.K.) exclusive distribution rights to market Remsima infliximab in the U....

Celltrion seeks FDA approval of biosimilar version of Remicade

Celltrion has filed an application with the FDA for approval to market Remsima, its biosimilar version of Johnson & Johnson a -More- 

Matching PubMed Articles


Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement